Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes - Tabular View

Tracking Information

First Received Date ^ICMJE

December 19, 2006

Last Updated Date

December 19, 2006

Start Date ^ICMJE

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Official Title ^ICMJE

Brief Summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Longitudinal, Convenience Sample, Prospective Study

Condition ^ICMJE

Healthy

Intervention ^ICMJE

Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

Patients not meeting above stated age criteria
Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
History of serious ocular, neurological, cardiovascular disease
History of severe systemic disease
History of arrhythmias or high blood pressure
Patients currently taking any type of ocular or systemic medications except multivitamins.
Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Gender

Both

Ages

18 Years to 50 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00413751

Responsible Party

Study ID Numbers ^ICMJE

WRAMC WU #03-23004

Study Sponsor ^ICMJE

Walter Reed Army Medical Center

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

KRAIG S. BOWER, MD

Walter Reed Army Medical Center

Information Provided By

Walter Reed Army Medical Center

Verification Date

December 2006

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP